Survival After Combining Stereotactic Body Radiation Therapy and Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma

Overview of attention for article published in Frontiers in oncology, February 2021

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (66th percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

policy: 1 policy source

twitter: 3 X users

Citations

dimensions_citation: 9 Dimensions

Readers on

mendeley: 16 Mendeley

Summary Policy documents X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 7,067 followers.

Experiencias similares se han descrito con el cáncer renal oligometastásico (incluyendo lesiones hilio-mediastínicas). SBRT 35-45 Gy en 5 fracciones + TKI: control local >90%. https://t.co/BJVLHW0rJc.

07 Feb 2022

Reply Repost Favourite

New research: Survival After Combining Stereotactic Body Radiation Therapy and Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma: Background Stereotactic body radiation therapy (SBRT) and tyrosine kinase inhibitors… https://t.co/9

29 Mar 2021

Reply Repost Favourite

Survival After Combining Stereotactic Body Radiation Therapy and Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma https://t.co/8j1uJwhR64

12 Mar 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.